Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals Inc., 23611-23612 [2024-07109]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 66 / Thursday, April 4, 2024 / Notices
Background
On February 14, 2024, Cornerstone
Chemical Company, Waggaman,
Louisiana, filed petitions with the
Commission and Commerce, alleging
that an industry in the United States is
materially injured or threatened with
material injury by reason of subsidized
imports of melamine from Germany,
India, Qatar, and Trinidad and Tobago
and LTFV imports of melamine from
Germany, India, Japan, Netherlands,
Qatar, and Trinidad and Tobago.
Accordingly, effective February 14,
2024, the Commission instituted
countervailing duty investigation Nos.
701–TA–706–709 and antidumping
duty investigation Nos. 731–TA–1667–
1672 (Preliminary).
Notice of the institution of the
Commission’s investigations and of a
public conference to be held in
connection therewith was given by
posting copies of the notice in the Office
of the Secretary, U.S. International
Trade Commission, Washington, DC,
and by publishing the notice in the
Federal Register of February 21, 2024
(89 FR 13090). The Commission
conducted its conference on March 6,
2024. All persons who requested the
opportunity were permitted to
participate.
The Commission made these
determinations pursuant to §§ 703(a)
and 733(a) of the Act (19 U.S.C.
1671b(a) and 1673b(a)). It completed
and filed its determinations in these
investigations on April 1, 2024. The
views of the Commission are contained
in USITC Publication 5503 (April 2024),
entitled Melamine from Germany, India,
Japan, Netherlands, Qatar, and
Trinidad and Tobago: Investigation Nos.
701 TA–706–709 and 731–TA–1667–
1672 (Preliminary).
By order of the Commission.
Issued: April 1, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024–07181 Filed 4–3–24; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
ddrumheller on DSK120RN23PROD with NOTICES1
Drug Enforcement Administration
[Docket No. DEA–1350]
Bulk Manufacturer of Controlled
Substances Application: Sterling
Wisconsin, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
VerDate Sep<11>2014
Sterling Wisconsin, LLC has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before June 3, 2024. Such persons
may also file a written request for a
hearing on the application on or before
June 3, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on February 27, 2024,
Sterling Wisconsin, LLC, W130N10497
Washington Drive, Germantown,
Wisconsin 53022–4448, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
SUMMARY:
17:01 Apr 03, 2024
Jkt 262001
Drug
code
Controlled substance
Lysergic Acid
Diethylamide.
Marihuana Extract .........
Marihuana ......................
Tetrahydrocannabinols ..
Mescaline ......................
5-Methoxy-N-NDimethyltryptamine.
Psilocybin ......................
Oliceridine ......................
Thebaine ........................
Alfentanil ........................
Schedule
7315
I
7350
7360
7370
7381
7431
I
I
I
I
I
7437
9245
9333
9737
I
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for commercial sale to its
customers. In reference to drug codes
7350 (Marihuana Extract), 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
23611
drug codes are authorized for this
registration.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07110 Filed 4–3–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1348]
Bulk Manufacturer of Controlled
Substances Application: Patheon
Pharmaceuticals Inc.
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Notice of application.
Patheon Pharmaceuticals Inc.
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before June 3, 2024. Such persons
may also file a written request for a
hearing on the application on or before
June 3, 2024.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on February 28, 2024,
Patheon Pharmaceuticals Inc., 2110 East
Galbraith Road, Cincinnati, Ohio
45237–1625, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
E:\FR\FM\04APN1.SGM
04APN1
23612
Federal Register / Vol. 89, No. 66 / Thursday, April 4, 2024 / Notices
Drug
code
Controlled substance
Gamma Hydroxybutyric
Acid.
Schedule
2010
I
I
I
The company plans to manufacture
the above listed controlled substance as
Active Pharmaceutical Ingredient that
will be further synthesized into Food
and Drug Administration-approved
dosage forms. No other activities for this
drug code are authorized for this
registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07109 Filed 4–3–24; 8:45 am]
BILLING CODE P
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on March 4, 2024, Lonza
Tampa, LLC., 4901 West Grace Street,
Tampa, Florida 33607–3805, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
DEPARTMENT OF JUSTICE
Schedule
[Docket No. DEA–1351]
Psilocybin ......................
Importer of Controlled Substances
Application: Lonza Tampa, LLC
The company plans to import drug
code 7437 (Psilocybin) as finished
dosage units for clinical trials, research,
and analytical purposes. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Lonza Tampa, LLC. has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 6, 2024. Such persons
may also file a written request for a
hearing on the application on or before
May 6, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
Drug
code
Controlled substance
Drug Enforcement Administration
VerDate Sep<11>2014
17:01 Apr 03, 2024
Jkt 262001
7437
I
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–07108 Filed 4–3–24; 8:45 am]
BILLING CODE 4410–09–P
electronic comments on or objections to
the issuance of the proposed registration
on or before June 3, 2024. Such persons
may also file a written request for a
hearing on the application on or before
June 3, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on February 27, 2024,
Benuvia Operations, LLC, 3950 North
Mays Street, Round Rock, Texas 78665,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Drug
code
Controlled substance
Marihuana Extract .........
I
7350
Schedule
II
The company plans to bulk
manufacture the listed controlled
substance for dosage formulation
development. No other activities for
these drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
Drug Enforcement Administration
[FR Doc. 2024–07111 Filed 4–3–24; 8:45 am]
[Docket No. DEA–1352]
BILLING CODE P
Bulk Manufacturer of Controlled
Substances Application: Benuvia
Operations, LLC
Employee Benefits Security
Administration
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Benuvia Operations, LLC has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
SUMMARY:
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
DEPARTMENT OF LABOR
Technical Correction to PTE 2016–11,
Exemption From Certain Prohibited
Transaction Restrictions: Northern
Trust Corporation (Together With Its
Current and Future Affiliates, Northern
Trust or the Applicant)
Employee Benefits Security
Administration (EBSA), Labor.
ACTION: Notice of Technical Correction.
AGENCY:
E:\FR\FM\04APN1.SGM
04APN1
]]>Agencies
[Federal Register Volume 89, Number 66 (Thursday, April 4, 2024)]
[Notices]
[Pages 23611-23612]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07109]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1348]
Bulk Manufacturer of Controlled Substances Application: Patheon
Pharmaceuticals Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Patheon Pharmaceuticals Inc. has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
June 3, 2024. Such persons may also file a written request for a
hearing on the application on or before June 3, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on February 28, 2024, Patheon Pharmaceuticals Inc., 2110
East Galbraith Road, Cincinnati, Ohio 45237-1625, applied to be
registered as a bulk manufacturer of the following basic class(es) of
controlled substance(s):
[[Page 23612]]
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
------------------------------------------------------------------------
The company plans to manufacture the above listed controlled
substance as Active Pharmaceutical Ingredient that will be further
synthesized into Food and Drug Administration-approved dosage forms. No
other activities for this drug code are authorized for this
registration.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-07109 Filed 4-3-24; 8:45 am]
BILLING CODE P
